Stopping anticoagulants can harm A-fib patients, study finds | CMS proposes payment rules for readmissions, quality programs | Vermont lowers minimum blood donation age
Advertisement
April 27, 2012
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP ⋅   FORWARD
Top Story
Stopping anticoagulants can harm A-fib patients, study finds
Patients with atrial fibrillation who discontinued anticoagulant treatment were at greater risk for strokes and blood clots, according to a study from researchers at Duke University and UCLA. The risk of excessive bleeding was similar for those taking warfarin and rivaroxaban.
HealthDay News (4/25) 
LinkedIn Twitter Facebook Google+ Email
Standards for Relationship Testing Laboratories, 10th ed and Guidance CD
This edition features new and revised requirements in areas such as first-time accreditation and autosomal markers. The accompanying Guidance CD-ROM provides recommendations on how to meet the RT Standards requirements. Click here to order your copy today!
Advertisement
Emerging Trends
CMS proposes payment rules for readmissions, quality programs
A CMS proposed rule would pay acute care hospitals 2.3% more for treating Medicare patients if inpatient quality reporting programs are in place. The agency also proposed a calculation for penalties assessed to hospitals with high 30-day readmission rates. CMS said it wants to add surgical site infections from cardiac implantable electronic device and iatrogenic pneumothorax with venous catheterization as conditions subject to hospital-acquired condition payment provisions for fiscal 2013.
HealthLeaders Media (4/25) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Vermont lowers minimum blood donation age
Vermont Gov. Peter Shumlin signed a bill that will lower the minimum age requirement for blood donation from 17 to 16, according to the American Red Cross. The change could mean 1,000 more donors annually.
WCAX-TV (Burlington, Vt.) (4/25),  VTDigger.org (Vermont)/American Red Cross/News release (4/26) 
LinkedIn Twitter Facebook Google+ Email
Cell treatment on track for Phase II stroke trial
The stem cell therapy ReN001 is being used in early clinical trials to treat 12 patients disabled by stroke, and an application is on track for a midstage study in 2013. The therapy is based on stem cell developer ReNeuron's lead neural stem cell line. ReNeuron is also developing treatments for peripheral arterial disease and retina diseases.
ProactiveInvestors.co.uk (U.K.) (4/27) 
LinkedIn Twitter Facebook Google+ Email
Broad Institute aims to help scientists digest Big Data
The Broad Institute has launched a cloud-based, open-source data management platform called GenomeSpace that incorporates a variety of bioinformatics tools, says Jill Mesirov, the Broad Institute's associate director and chief informatics officer.
InternetEvolution.com (4/25) 
LinkedIn Twitter Facebook Google+ Email
.
Featured Content
Sponsored content from Northwestern University Kellogg School of Management
Click here to learn more about Featured Content
Government & Regulatory
Bill seeking stronger FDA oversight of medical devices advances
A Senate panel on Wednesday cleared a bill that would allow the FDA to evaluate the safety of approved medical devices and give conditional approvals dependent on further studies. The measure also would tighten the agency's 510(k) process that permits firms to prove the similarity of their devices to products already approved without needing extensive trials.
MassDevice.com (Boston) (4/25) 
LinkedIn Twitter Facebook Google+ Email
FDA warns against combining hepatitis C treatment, some HIV drugs
The FDA is revising the label of boceprevir, a recently approved hepatitis C treatment, to warn about co-administration with certain HIV medicines. Taking boceprevir with some HIV drugs, including ritonavir, might increase the level of either virus in the blood, the agency said.
Chicago Tribune (tiered subscription model)/Reuters (4/26) 
LinkedIn Twitter Facebook Google+ Email
Coalition presses for change in drug tracking bill
Disagreements between the FDA and the health care industry could sink plans to establish a national system for tracking and tracing pharmaceuticals. A group of drug manufacturers, distributors and pharmacies says tracking drug lots -- rather than individual packages, as the FDA proposes -- would be cheaper and simpler to implement.
Reuters (4/25) 
LinkedIn Twitter Facebook Google+ Email
Association News
2012 ASCP wage and vacancy survey deadline is Monday
Monday, April 30, is the deadline for completing the American Society for Clinical Pathology's 13th Wage and Vacancy Survey, which collects the most recent wage data and determines the extent and distribution of shortages within the nation's clinical laboratory workforce. The vacancy component of the survey will be distributed in May. The wage component will include information submitted by both ASCP members and individuals certified by ASCP. Specialists in Blood Banking are particularly encouraged to participate, as the response rate among this professional group has been low in previous years. Complete the survey.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
JOBS
powered by
Director, Regional Quality
BLOOD SYSTEMS, INC. - 
Performance Improvement Consultant
BLOOD SYSTEMS, INC. - 
Country Director - Mozambique
AABB - 
Senior Project Manager
BLOOD SYSTEMS, INC. - 
Transfusion Safety Coordinator
PACIFIC DIAGNOSTIC LABORATORIES, LLC - 
Standards Development Specialist
AABB - 
(CEO), Greater Ozarks Region
AMERICAN RED CROSS - 
Deputy Director, Regulatory Affairs - Cellular Therapy
AABB - 
  
  
Ideas are like rabbits. You get a couple and learn how to handle them, and pretty soon you have a dozen.
John Steinbeck,
American writer
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information